Pediatric cancer treatment and hazardous drug exposure control: A pharmacist perspective on safety and reassurance for children and their families

Abstract

Anticancer drug therapy is a central component of pediatric cancer treatment and is essential for saving children’s lives. However, its potent toxicity has introduced a new source of anxiety known as “exposure risk,” not only for patients but also for their families and healthcare providers. In recent years, the development of novel anticancer agents and advances in treatment strategies have made combination chemotherapy involving multiple agents the standard approach. As a result, exposure risks have become more complex and diverse.

In this symposium, the concept of “appropriate awareness of risk” was adopted as a key theme. The objective was to promote an accurate understanding of the risks associated with exposure to anticancer drugs and to share practical preventive measures that can be implemented in daily life. Effective communication has become increasingly important in pediatric oncology because information regarding exposure prevention must be conveyed in an understandable manner to children and their families.

At present, no unified standards exist for preventing exposure to anticancer drugs, and the most appropriate strategies have not been clearly established. Nevertheless, presenting feasible practices that can be implemented in clinical settings for children and their families is an important role for pharmacists involved in cancer care. Through collaboration among physicians, nurses, and other healthcare professionals, children and their families are expected to gain an accurate understanding of exposure risks and participate in cancer treatment with confidence under appropriate protective measures.